Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind Study to Evaluate the Effectiveness and Safety of RWJ-333369 [carisbamate] as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures.

Trial Profile

A Double-Blind Study to Evaluate the Effectiveness and Safety of RWJ-333369 [carisbamate] as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carisbamate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors SK Life Science
  • Most Recent Events

    • 01 Aug 2012 SK Life Science added as trial association and lead trial centre as reported by ClinicalTrials.gov (Parent trial: NCT00697762).
    • 17 Mar 2011 Actual end date is Apr 2009 for extension trial ClinicalTrials.gov.
    • 17 Mar 2011 Actual initiation date is Mar 2008 according to extension trial ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top